This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gökmen-Polar, Y. Articles by Sledge, G. W. Search for Related Content PubMed PubMed Citation Articles by Gökmen-Polar, Y. Articles by Sledge, G. W., Jr.

ß-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells

Departments of ¹ Medicine, ² Biochemistry and Molecular Biology, and ³ Pathology and Laboratory Medicine, Indiana University School of Medicine, and ⁴ Indiana Centers for Applied Protein Sciences, Indianapolis, Indiana; ⁵ Winship Cancer Institute, Emory University, Atlanta, Georgia; ⁶ Medical Oncology Center, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; and ⁷ EntreMed, Inc., Rockville, Maryland

Requests for reprints: Yesim Gökmen-Polar, Indiana Cancer Research Institute, 1044 West Walnut Street, R4-202 Indianapolis, IN 46202-5254. Phone: 317-274-3605; Fax: 317-274-0396; E-mail: ypolar{at}iupui.edu.

2-Methoxyestradiol is an estradiol metabolite with significant antiproliferative and antiangiogenic activity independent of estrogen receptor status. To identify a molecular basis for acquired 2-methoxyestradiol resistance, we generated a stable 2-methoxyestradiol-resistant (2ME2R) MDA-MB-435 human cancer cell line by stepwise exposure to increasing 2-methoxyestradiol concentrations. 2ME2R cells maintained in the presence of the drug and W435 cells maintained in the absence of the drug showed 32.34- to 40.07-fold resistance to 2-methoxyestradiol. Cross-resistance was observed to Vinca alkaloids, including vincristine, vinorelbine, and vinblastine (4.29- to 6.40-fold), but minimal resistance was seen to colchicine-binding agents including colchicine, colcemid, and AVE8062A (1.72- to 2.86-fold). No resistance was observed to paclitaxel and epothilone B, polymerizing agents (0.89- to 1.14-fold). Genomic sequencing identified two different heterozygous point mutations in the class I (M40) isotype of ß-tubulin at amino acids 197 (Dß197N) and 350 (Kß350N) in 2ME2R cells. Tandem mass spectrometry confirmed the presence of both wild-type and the mutant ß-tubulin in 2ME2R cells at the protein level. Consistently, treatment of parental P435 cells with 2-methoxyestradiol resulted in a dose-dependent depolymerization of microtubules, whereas 2ME2R cells remained unaffected. In contrast, paclitaxel affected both cell lines. In the absence of 2-methoxyestradiol, 2ME2R cells were characterized by an elevated level of detyrosination. Upon 2-methoxyestradiol treatment, levels of acetylated and detyrosinated tubulins decreased in P435 cells, while remaining constant in 2ME2R cells. These results, together with our structure-based modeling, show a tight correlation between the antitubulin and antiproliferative effects of 2-methoxyestradiol, consistent with acquired tubulin mutations contributing to 2-methoxyestradiol resistance.

This article has been cited by other articles:

				T. Y.E. Liaw, N. K. Salam, M. J. McKay, A. M. Cunningham, D. E. Hibbs, and M. Kavallaris Class I {beta}-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions Mol. Cancer Ther., October 1, 2008; 7(10): 3150 - 3159. [Abstract] [Full Text] [PDF]

				A.-M. Liberatore, H. Coulomb, D. Pons, O. Dutruel, P. G. Kasprzyk, M. Carlson, A. S. Nelson, S. P. Newman, C. Stengel, P. Auvray, et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther., August 1, 2008; 7(8): 2426 - 2434. [Abstract] [Full Text] [PDF]

				T. M. LaVallee, P. A. Burke, G. M. Swartz, E. Hamel, G. E. Agoston, J. Shah, L. Suwandi, A. D. Hanson, W. E. Fogler, C. F. Sidor, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198 Mol. Cancer Ther., June 1, 2008; 7(6): 1472 - 1482. [Abstract] [Full Text] [PDF]

				S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al. STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606. [Abstract] [Full Text] [PDF]

				U. Eichenlaub-Ritter, U. Winterscheidt, E. Vogt, Y. Shen, H.-R. Tinneberg, and R. Sorensen 2-Methoxyestradiol Induces Spindle Aberrations, Chromosome Congression Failure, and Nondisjunction in Mouse Oocytes Biol Reprod, May 1, 2007; 76(5): 784 - 793. [Abstract] [Full Text] [PDF]

				R. Bhati, Y. Gokmen-Polar, G. W. Sledge Jr., C. Fan, H. Nakshatri, D. Ketelsen, C. H. Borchers, M. J. Dial, C. Patterson, and N. Klauber-DeMore 2-Methoxyestradiol Inhibits the Anaphase-Promoting Complex and Protein Translation in Human Breast Cancer Cells Cancer Res., January 15, 2007; 67(2): 702 - 708. [Abstract] [Full Text] [PDF]

				J. S. Owen, M. S. Bharadwaj, M. J. Thomas, S. Bhat, M. P. Samuel, and M. G. Sorci-Thomas Ratio determination of plasma wild-type and L159R apoA-I using mass spectrometry: tools for studying apoA-IFin J. Lipid Res., January 1, 2007; 48(1): 226 - 234. [Abstract] [Full Text] [PDF]

				S.-H. Kang, H. T. Cho, S. Devi, Z. Zhang, D. Escuin, Z. Liang, H. Mao, D. J. Brat, J. J. Olson, J. W. Simons, et al. Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model Cancer Res., December 15, 2006; 66(24): 11991 - 11997. [Abstract] [Full Text] [PDF]

				S. A. Salama, A. B. Nasr, R. K. Dubey, and A. Al-Hendy Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids Reproductive Sciences, December 1, 2006; 13(8): 542 - 550. [Abstract] [PDF]